Deuterium-Enriched Bupropion Therapeutic Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current bupropion pharmaceuticals have limitations in achieving therapeutic efficacy due to natural abundance of deuterium, which restricts their effectiveness as antidepressants and smoking cessation aids.
Innovation Solution
Development of deuterium-enriched bupropion or its pharmaceutically acceptable salts, achieved by exchanging hydrogen atoms with deuterium or using deuterated starting materials, to exceed natural deuterium abundance, resulting in novel compositions for enhanced therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natural abundance deuterium is used in bupropion, then the compound is readily available and easy to manufacture, but the therapeutic efficacy is limited
Solution Approach 1:
The patent applies parameter changes by modifying the deuterium abundance parameter from natural levels (0.015%) to enriched levels (greater than 5%, preferably greater than 10%). This parameter change directly addresses the limitation of natural abundance deuterium by increasing the deuterium content to achieve enhanced therapeutic efficacy while maintaining the same chemical structure and pharmaceutical properties of bupropion.
2Reliability
If deuterium enrichment is increased to improve therapeutic effects, then efficacy as antidepressant and smoking cessation aid is enhanced, but manufacturing complexity increases
Solution Approach 1:
The patent resolves this contradiction by systematically changing the deuterium enrichment parameter to specific ranges (greater than 5%, preferably greater than 10%, more preferably greater than 20%). These defined parameter ranges provide a balance between achieving enhanced therapeutic efficacy and maintaining manufacturability, avoiding excessive complexity while ensuring clinical effectiveness.
Solution Approach 2:
The patent applies local quality by selectively deuterating specific positions on the bupropion molecule rather than uniformly enriching all hydrogen positions. This selective approach focuses deuterium enrichment at key metabolic sites to maximize therapeutic benefit while minimizing the overall manufacturing complexity and cost associated with complete deuteration.
Data Source
AI summary
The present application describes deuterium-enriched bupropion, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.